Neurocrine Biosciences Inc. Common Stock (NBIX)

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenit…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

2,500

Website

www.neurocrine.com

Fundamentals

1-day range

$148.78$153.42

Market cap

$16.71B

P/E (trailing)

22.33

P/E (forward)

12.78

EPS (trailing)

$6.84

Dividend yield

—

Beta

0.39

Avg. volume

1.26M

Ex-dividend date

December 29, 1995

Forecasts

27 analyst ratings

Neurocrine Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• NBIX

  Neurocrine Biosciences Inc. Common Stock

  $153.98

  ▼ 1.24%
  Market cap $16.71BP/E 22.33
  $122.14$186.12
• MRNA

  Moderna Inc. Common Stock

  $137.93

  ▼ 3.39%
  Market cap $21.88BP/E —
  $22.28$176.66
• BNTX

  BioNTech SE American Depositary Share

  $102.04

  ▼ 8.40%
  Market cap $23.18BP/E —
  $79.52$124
• HALO

  Halozyme Therapeutics Inc. Common Stock

  $105.33

  ▼ 1.49%
  Market cap $9.76BP/E 27.63
  $61.23$109.66
• QGEN

  Qiagen N.V. Common Shares

  $43.12

  ▼ 1.43%
  Market cap $8.72BP/E 22.14
  $32.53$57.82
• KYMR

  Kymera Therapeutics Inc. Common Stock

  $118.08

  ▼ 1.79%
  Market cap $8.25BP/E —
  $39.84$130.05
• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.78BP/E —
  $44.12$78.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Neurocrine Biosciences: 'House Full Of Options'
  SeekingAlpha · 8/22/2026
• 10 Health Care Stocks Whale Activity In Today’s Session
  Benzinga · 8/21/2026
• Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
  Yahoo · 8/20/2026
• Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
  Yahoo · 8/20/2026
• Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
  Benzinga · 8/18/2026
• NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
  Yahoo · 8/17/2026
• Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182
  Benzinga · 8/13/2026
• NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings
  Yahoo · 8/12/2026

• Jude Onyia · August 4, 2026 · Gift

  2.4K
• Leslie Norwalk V · July 29, 2026 · Option Exercise

  842 @ $139.43
• Leslie Norwalk V · July 28, 2026 · Sale

  1.3K @ $182.01
• Ingrid Delaet · July 10, 2026 · Option Exercise

  4.4K @ $106.02
• Ingrid Delaet · July 10, 2026 · Sale

  4.4K @ $181.02
• Ingrid Delaet · July 9, 2026 · Option Exercise

  8.4K @ $103.52
• Ingrid Delaet · July 9, 2026 · Sale

  8.4K @ $178.72
• Darin Lippoldt · July 9, 2026 · Option Exercise

  10.0K @ $81.49
• Darin Lippoldt · July 9, 2026 · Sale

  10.0K @ $179.6
• Ingrid Delaet · July 8, 2026 · Option Exercise

  2.7K @ $103.52
• Ingrid Delaet · July 8, 2026 · Sale

  2.7K @ $178.54
• Ingrid Delaet · July 7, 2026 · Option Exercise

  3.4K @ $103.52
• Ingrid Delaet · July 7, 2026 · Sale

  3.4K @ $178.57
• Jude Onyia · June 5, 2026 · Gift

  2.4K
• Stephen A. Sherwin · June 5, 2026 · Option Exercise

  10.0K @ $79.79

Institutional Ownership

March 31, 2026

Total shares held

89.06M

Total value held

$11.42B

Institutional holders

680